Sorry, you need to enable JavaScript to visit this website.
Skip to main content

All materials and content available on the website are of strictly non-promotional nature and only intended for healthcare professionals (HCPs) practicing in Europe. Kindly note that materials and content are not intended for any specific country and approval conditions for products may vary from country to country. Before prescribing any product, always refer to the approved label in the relevant country and/or the Summary of Product Characteristics.

  • June 30, 2022
  • ANCA-associated vasculitis

ANCA 2022 Symposia: Transforming outcomes in AAV by targeting C5aR-mediated inflammation

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Exploring the unmet needs of people suffering with ANCA-associated vasculitis (AAV)

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

AAV Disease awareness MoD video

Explore the science
  • June 08, 2022
  • Hyperkalemia

Optimization of RAASi and low risk of hyperkalemia with potassium binder in HFrEF

Explore the science
  • February 18, 2022
  • CKD-MBD and SHPT

Establishing 25(OH)D-level adequacy in patients with ND-CKD

Explore the science
  • February 18, 2022
  • CKD-MBD and SHPT

Emerging opportunities and challenges in SHPT

Explore the science
  • February 18, 2022
  • CKD-MBD and SHPT

Practical approaches to SHPT management in patients with ND-CKD

Explore the science
  • February 18, 2022
  • CKD-MBD and SHPT

Unmet needs in the treatment of SHPT

Explore the science
  • February 18, 2022
  • Hyperkalemia

The latest KDIGO guidelines support the use of next-generation potassium binders for the management of chronic hyperkalemia

Explore the science